After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, DVAX falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Dynavax Technologies Corp is $1.23B. A total of 3.7 million shares were traded on the day, compared to an average of 1.61M shares.
In the most recent transaction, Deep Track Biotechnology Maste sold 1,094,994 shares of DVAX for 11.03 per share on Aug 21 ’25. After the transaction, the 10% Owner now owns 16,696,492 company shares. In a previous transaction on Aug 22 ’25, Deep Track Biotechnology Maste sold 970,143 shares at 10.59 per share. DVAX shares that 10% Owner owns now total 15,726,349.
Among the insiders who sold shares, Novack David F disposed of 10,000 shares on Mar 24 ’25 at a per-share price of $14.00. This resulted in the President & COO holding 8,078 shares of DVAX after the transaction. In another insider transaction, DAVID NOVACK bought 10,000 shares at $14.00 per share on Mar 24 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, DVAX has a high of $14.63 and a low of $9.22.
As of this writing, DVAX has an earnings estimate of $0.15 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.15 per share and a lower estimate of $0.15. The company reported an EPS of $0.12 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. DVAX’s latest balance sheet shows that the firm has $545.95M in Cash & Short Term Investments as of fiscal 2021. There were $257.38M in debt and $556.40M in liabilities at the time. Its Book Value Per Share was $4.22, while its Total Shareholder’s Equity was $222.37M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DVAX is Buy with a score of 3.80.
